Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| LTS12869 | Other Identifier | Sanofi | |
| U1111-1163-0368 | Other Identifier | UTN | |
| 2021-005552-11 | EudraCT Number |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Pompe disease (also known as glycogen storage disease Type II) is a rare autosomal recessive metabolic muscle disease caused by the deficiency of acid α glucosidase (GAA), an enzyme that degrades lysosomal glycogen. As opposed to the exclusively cytoplasmic accumulation of glycogen that occurs in other glycogen storage disorders, Pompe disease is characterized by organelle bound (lysosomal) and extra-lysosomal accumulation of glycogen in many body tissues, ultimately leading to multisystemic pathology. The overall objective of this study was to evaluate the long-term growth and development of participants with infantile-onset Pompe disease with alglucosidase alfa before 1 year of age. Participants were to be followed for a 10-year period.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Alglucosidase Alfa | Experimental | Participants received alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight as intravenous infusion every 2 weeks and were followed for 10 years or up to discontinuation from study treatment due to any reason. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| alglucosidase alfa | Biological | Dose: 20 mg/kg every 2 weeks; Route of administration: Intravenous infusion |
|
| Measure | Description | Time Frame |
|---|---|---|
| Recumbent Height/Length of Participants in Centimeters (cm) | Height/Length of Participants was measured in centimeters. Week is denoted as Wk in time frame section. | Participants 1-12:Baseline, Participant1: Wk 52, Participant2: Wk82, Participants 3-4: Wk208, Participant5: Wk12, Participant6: Wk365, Participant7: Wk64, Participant8:Wk156, Participant9:Wk364, Participant10:Wk52, Participant11:Wk156, Participant12:Wk520 |
| Body Weight of Participants in Kilograms (kg) | Body Weight of Participants was measured in Kilograms (kg). Week is denoted as Wk in time frame section. | Participant1-12:Baseline, Participant1:Wk 52, Participant2:Wk82, Participant3: Wk208,Participant4:Wk364,Participant5:Wk12,Participant6:Wk365,Participant7:Wk64,Participant8:Wk156,Participant9:Wk364,Participant10:Wk52,Participant11:Wk156,Participant12:Wk520 |
| Head Circumference of Participants in Centimeters (cm) | Head Circumference of Participants was measured in Centimeters. | Participants1-12:Baseline, Participant1:Week(Wk)52, Participant2:Wk82, Participants3and4:Wk208, Participant5:Wk12, Participant6:Wk365, Participant7:Wk64, Participant8:Wk156, Participant9:Wk312, Participant10:Wk52, Participant11:Wk156, Participant12:Wk468 |
| Motor Subscale of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite Scores | Bayley-III: Instrument designed to measure developmental functioning of infants and toddlers between ages of 1 and 42 months (age adjustments for prematurity are accommodated with tool). Bayley-III administered up to 42 months of age and provides age specific norm-referenced composite scores for cognitive scales (91 items, composite score minimum 55 and maximum 145), language scale (98 items, composite score minimum 47 and maximum 153), motor scale (138 items, composite score minimum 46 and maximum 154) skills. For all raw scores (for scales), higher scores indicates greater number of developmental skills credited. For norm-based composite scales for motor scale, score of 100 defines average performance of given age group, scores of 85 and 115 are 1 standard deviation (SD) below an above mean, respectively, and scores of 70 and 130 are equivalent to 2 SD from mean. |
| Measure | Description | Time Frame |
|---|---|---|
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Adverse event (AE): any undesirable physical, psychological or behavioral effect experienced by participants during their participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. Any untoward signs or symptoms experienced by the participant from the time of signing of the informed consent until completion of the study. Serious AE (SAE): any AE that resulted in any of the following outcomes: death, life-threatening experience, required hospitalization or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, and important medical events. TEAEs: AEs that developed, worsened, or became serious during the treatment-emergent period (defined as the period from the first study drug administration until last study assessment). |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Monitor | Genzyme, a Sanofi Company | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Gainesville | Florida | United States | ||||
Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org
Not provided
Not provided
Not provided
Not provided
All 12 participants were enrolled and treated in the study.
The study was conducted at 3 active sites in United States. A total of 12 participants were screened from 26-August-2008 to 07-February-2014.
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Alglucosidase Alfa | Participants received alglucosidase alfa 20 milligrams per kilogram (mg/kg) body weight as intravenous infusion every 2 weeks and were followed for 10 years or up to discontinuation from study treatment due to any reason. |
| Title | Milestones | Reasons Not Completed | ||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Overall Study |
|
|
Analysis was performed on full analysis set (FAS) that included all enrolled participants who had received at least one infusion (complete or partial) of alglucosidase alfa.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Alglucosidase Alfa | Participants received alglucosidase alfa 20 mg/kg body weight as intravenous infusion every 2 weeks and were followed for 10 years or up to discontinuation from study treatment due to any reason. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes |
|---|---|---|---|---|---|---|---|---|---|
| Age, Continuous | Mean |
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Recumbent Height/Length of Participants in Centimeters (cm) | Height/Length of Participants was measured in centimeters. Week is denoted as Wk in time frame section. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | cm | Participants 1-12:Baseline, Participant1: Wk 52, Participant2: Wk82, Participants 3-4: Wk208, Participant5: Wk12, Participant6: Wk365, Participant7: Wk64, Participant8:Wk156, Participant9:Wk364, Participant10:Wk52, Participant11:Wk156, Participant12:Wk520 |
|
From administration of first dose of study drug up to 13.25 years
Reported AEs and deaths are TEAEs that developed, worsened, or became serious during the treatment period (from the first administration of study drug in the study to the last study assessment). Analysis was performed on FAS population.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Alglucosidase Alfa | Participants received alglucosidase alfa 20 mg/kg body weight as intravenous infusion every 2 weeks until 10 years of age or up to discontinuation from study treatment due to any reason. |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Bacteraemia | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Ear Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
No summary analysis was done and participant wise data were reported at available specified timepoints. Reporting of participant numbers is per-endpoint and not consistent between assessments to maintain participant's privacy.
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| Trial Transparency Team | Sanofi | 800-633-1610 | 6# | Contact-US@sanofi.com |
Not provided
| Type | Includes Protocol | Includes SAP | Includes ICF | Document Label | Document Date | Document Uploaded Date | Document File Name |
|---|---|---|---|---|---|---|---|
| Prot | Yes | No | No | Study Protocol | Dec 2, 2014 | Jul 29, 2022 | Prot_000.pdf |
| SAP | No | Yes | No | Statistical Analysis Plan | Sep 27, 2021 | Jul 29, 2022 | SAP_001.pdf |
Not provided
| ID | Term |
|---|---|
| D006009 | Glycogen Storage Disease Type II |
| ID | Term |
|---|---|
| D020140 | Lysosomal Storage Diseases, Nervous System |
| D020739 | Brain Diseases, Metabolic, Inborn |
| D001928 | Brain Diseases, Metabolic |
| D001927 | Brain Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C509951 | GAA protein, human |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11: Week 26, Participant-12: Week 104 |
| Gross Motor Function Measure (GMFM-88) Total Scores | GMFM-88 is developed specifically to detect quantitative changes in gross motor function that consists of 88 items organized into 5 dimensions: lying and rolling, sitting, crawling and kneeling, standing, and walking, running and jumping. Each item is scored on a 4-point Likert scale that ranges from 0 to 3, i.e., 0=cannot do; 1=initiated (less than [<] 10 percent [%] of task); 2=partially completed (10 to <100% of task); 3=task completion. The score for each dimension is expressed as percentage of the maximum score for that dimension. Total GMFM-88 score is obtained by adding percentage score for each dimension and dividing the sum by total number of dimensions. Total score ranges from 0 to 100, where higher score indicates better gross motor functions. | Participants 1-12: Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 26, Participant-8: Wk 156, Participant-9: Wk 312, Participant-11: Wk 156, Participant-12: Wk416 |
| Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) Scaled Scores | Pompe PEDI is disease specific version of PEDI developed to assess functional capabilities and performance in children with Pompe disease from 2 months up to adolescence. It consists of all items of original PEDI Functional Skills Scales and Caregiver Assistance Scales for three content domains: self-care, mobility, and social function. Additional items were added to Functional Skills Scales Mobility and Self-care domains. Norm-based scoring is developed for additional items and scoring algorithms for PEDI are adjusted to reflect normative data collected for Pompe PEDI. Scaled scores for each domain range from 0-100 and provide indication of performance of child along continuum of relatively easy to relatively difficult items in particular domain of PEDI, where higher score indicates increased degrees of functional performance. | Participants1-12:Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 52, Participant-8: Wk156, Participant-9: Wk 312, Participant-10: Wk 26, Participant-11: Wk 156, Participant-12: Wk 416 |
| Cognitive and Language Subscales of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite Scores | Bayley-III: Instrument designed to measure developmental functioning of infants and toddlers between ages of 1 and 42 months (age adjustments for prematurity are accommodated with tool). Bayley-III administered up to 42 months of age and provides age specific norm-referenced composite scores for cognitive scales (91 items, composite score minimum 55 and maximum 145), language scale (98 items, composite score minimum 47 and maximum 153), motor scale (138 items, composite score minimum 46 and maximum 154) skills. For all raw scores (for scales), higher scores indicates greater number of developmental skills credited. For norm-based composite scales for cognitive and language, score of 100 defines average performance of given age group, scores of 85 and 115 are 1 SD below an above mean, respectively, and scores of 70 and 130 are equivalent to 2 SD from mean. | Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11:Week 26, Participant-12: Week 104 |
| Brief Intelligence Quotient (IQ) Score of the Leiter International Performance Scale-Revised (Leiter-R) | Leiter Scale is designed as nonverbal measure of intellectual function, memory and attention for Participants with communication disorders, hearing impairments, motor impairments, certain types of learning disabilities. Leiter-R was administered to participants after aging out of Bayley-III (at 42 months of age) and before Leiter-3 utilization (per protocol, due to discontinuation of Leiter-R). Leiter-R scale consists of 2 groups of subtests: Visualization-Reasoning Battery, Attention-Memory Battery. Subtests in Leiter-R were Figure Ground, Form Completion, Sequential Order, Repeated Patterns using that 'Brief Scale IQ' was scored for estimation of intellectual ability. Brief-IQ scores range is 30-170, where higher scores indicates higher intelligence. Score of 100 is expected mean standard score at each age interval. 95% children in each age group (based on normative sample) are expected to score within 2 SD of mean. | Participants 1 and 2: Week 156, Participant-3: Week 260, Participant-4: Week 156, Participant-5: Week 208 |
| Nonverbal Intelligence Quotient (IQ) Score of Leiter International Performance Scale - 3rd Edition (Leiter-3) | Leiter Scale: Designed as nonverbal measure of intellectual function, memory and attention for participants with communication disorders, hearing impairments, motor impairments, certain types of learning disabilities. Leiter-3 has 2 groups of subtests: cognitive battery and attention/memory battery. Nonverbal intelligence estimates global intellectual ability. The 4 cognitive battery subtests are: Figure Ground, Form Completion, Sequential Order, Classification-analogies along with 1 optional subset, Visual Patterns. Nonverbal IQ scores range is 30-170, which encompass 'severe delay' to 'extremely high/gifted', higher numbers indicates higher intelligence. Score of 100 is expected mean standard score at each age interval. 95% children in each age group (based on normative sample) are expected to score within 2 SD of mean. | Participant-1: Week 156, Participant-2: Week 312, Participant-3: Week 416 |
| From Baseline up to 13.25 years |
| Decatur |
| Georgia |
| United States |
| Detroit | Michigan | United States |
| months |
|
| Sex: Female, Male | Count of Participants | Participants |
|
| Race (NIH/OMB) | Count of Participants | Participants |
|
| Recumbent Height/Length of Participants at Baseline | Mean | Standard Deviation | centimeter (cm) |
|
| Body Weight of Participants at Baseline | Mean | Standard Deviation | kilogram (Kg) |
|
| Head Circumference of Participants at Baseline | Mean | Standard Deviation | cm |
|
| Units | Counts |
|---|---|
| Participants |
|
|
| Primary | Body Weight of Participants in Kilograms (kg) | Body Weight of Participants was measured in Kilograms (kg). Week is denoted as Wk in time frame section. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | kilograms | Participant1-12:Baseline, Participant1:Wk 52, Participant2:Wk82, Participant3: Wk208,Participant4:Wk364,Participant5:Wk12,Participant6:Wk365,Participant7:Wk64,Participant8:Wk156,Participant9:Wk364,Participant10:Wk52,Participant11:Wk156,Participant12:Wk520 |
|
|
|
| Primary | Head Circumference of Participants in Centimeters (cm) | Head Circumference of Participants was measured in Centimeters. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | cm | Participants1-12:Baseline, Participant1:Week(Wk)52, Participant2:Wk82, Participants3and4:Wk208, Participant5:Wk12, Participant6:Wk365, Participant7:Wk64, Participant8:Wk156, Participant9:Wk312, Participant10:Wk52, Participant11:Wk156, Participant12:Wk468 |
|
|
|
| Primary | Motor Subscale of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite Scores | Bayley-III: Instrument designed to measure developmental functioning of infants and toddlers between ages of 1 and 42 months (age adjustments for prematurity are accommodated with tool). Bayley-III administered up to 42 months of age and provides age specific norm-referenced composite scores for cognitive scales (91 items, composite score minimum 55 and maximum 145), language scale (98 items, composite score minimum 47 and maximum 153), motor scale (138 items, composite score minimum 46 and maximum 154) skills. For all raw scores (for scales), higher scores indicates greater number of developmental skills credited. For norm-based composite scales for motor scale, score of 100 defines average performance of given age group, scores of 85 and 115 are 1 standard deviation (SD) below an above mean, respectively, and scores of 70 and 130 are equivalent to 2 SD from mean. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | score on a scale | Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11: Week 26, Participant-12: Week 104 |
|
|
|
| Primary | Gross Motor Function Measure (GMFM-88) Total Scores | GMFM-88 is developed specifically to detect quantitative changes in gross motor function that consists of 88 items organized into 5 dimensions: lying and rolling, sitting, crawling and kneeling, standing, and walking, running and jumping. Each item is scored on a 4-point Likert scale that ranges from 0 to 3, i.e., 0=cannot do; 1=initiated (less than [<] 10 percent [%] of task); 2=partially completed (10 to <100% of task); 3=task completion. The score for each dimension is expressed as percentage of the maximum score for that dimension. Total GMFM-88 score is obtained by adding percentage score for each dimension and dividing the sum by total number of dimensions. Total score ranges from 0 to 100, where higher score indicates better gross motor functions. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | score on a scale | Participants 1-12: Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 26, Participant-8: Wk 156, Participant-9: Wk 312, Participant-11: Wk 156, Participant-12: Wk416 |
|
|
|
| Primary | Pompe Pediatric Evaluation of Disability Inventory (Pompe PEDI) Scaled Scores | Pompe PEDI is disease specific version of PEDI developed to assess functional capabilities and performance in children with Pompe disease from 2 months up to adolescence. It consists of all items of original PEDI Functional Skills Scales and Caregiver Assistance Scales for three content domains: self-care, mobility, and social function. Additional items were added to Functional Skills Scales Mobility and Self-care domains. Norm-based scoring is developed for additional items and scoring algorithms for PEDI are adjusted to reflect normative data collected for Pompe PEDI. Scaled scores for each domain range from 0-100 and provide indication of performance of child along continuum of relatively easy to relatively difficult items in particular domain of PEDI, where higher score indicates increased degrees of functional performance. | Analysis was preformed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoint. | Posted | Number | score on a scale | Participants1-12:Baseline, Participants 1 and 2: Wk 52, Participants 3 and 4: Wk 208, Participant-6: Wk 359, Participant-7: Wk 52, Participant-8: Wk156, Participant-9: Wk 312, Participant-10: Wk 26, Participant-11: Wk 156, Participant-12: Wk 416 |
|
|
|
| Primary | Cognitive and Language Subscales of Bayley Scales of Infant and Toddler Development, Third Edition (Bayley-III) Normative Composite Scores | Bayley-III: Instrument designed to measure developmental functioning of infants and toddlers between ages of 1 and 42 months (age adjustments for prematurity are accommodated with tool). Bayley-III administered up to 42 months of age and provides age specific norm-referenced composite scores for cognitive scales (91 items, composite score minimum 55 and maximum 145), language scale (98 items, composite score minimum 47 and maximum 153), motor scale (138 items, composite score minimum 46 and maximum 154) skills. For all raw scores (for scales), higher scores indicates greater number of developmental skills credited. For norm-based composite scales for cognitive and language, score of 100 defines average performance of given age group, scores of 85 and 115 are 1 SD below an above mean, respectively, and scores of 70 and 130 are equivalent to 2 SD from mean. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints. | Posted | Number | score on a scale | Participants 1-12: Baseline, Participant-1: Week 52, Participant-2: Week 83, Participants 3 and 4: Week 104, Participant-6: Week 78, Participants 7 and 8: Week 26, Participant-9: Week 156, Participants 10 and 11:Week 26, Participant-12: Week 104 |
|
|
|
| Primary | Brief Intelligence Quotient (IQ) Score of the Leiter International Performance Scale-Revised (Leiter-R) | Leiter Scale is designed as nonverbal measure of intellectual function, memory and attention for Participants with communication disorders, hearing impairments, motor impairments, certain types of learning disabilities. Leiter-R was administered to participants after aging out of Bayley-III (at 42 months of age) and before Leiter-3 utilization (per protocol, due to discontinuation of Leiter-R). Leiter-R scale consists of 2 groups of subtests: Visualization-Reasoning Battery, Attention-Memory Battery. Subtests in Leiter-R were Figure Ground, Form Completion, Sequential Order, Repeated Patterns using that 'Brief Scale IQ' was scored for estimation of intellectual ability. Brief-IQ scores range is 30-170, where higher scores indicates higher intelligence. Score of 100 is expected mean standard score at each age interval. 95% children in each age group (based on normative sample) are expected to score within 2 SD of mean. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints (most recent visit). Here, "Overall number of participants analyzed" signifies participants who were evaluated for this outcome measure. | Posted | Number | score on a scale | Participants 1 and 2: Week 156, Participant-3: Week 260, Participant-4: Week 156, Participant-5: Week 208 |
|
|
|
| Primary | Nonverbal Intelligence Quotient (IQ) Score of Leiter International Performance Scale - 3rd Edition (Leiter-3) | Leiter Scale: Designed as nonverbal measure of intellectual function, memory and attention for participants with communication disorders, hearing impairments, motor impairments, certain types of learning disabilities. Leiter-3 has 2 groups of subtests: cognitive battery and attention/memory battery. Nonverbal intelligence estimates global intellectual ability. The 4 cognitive battery subtests are: Figure Ground, Form Completion, Sequential Order, Classification-analogies along with 1 optional subset, Visual Patterns. Nonverbal IQ scores range is 30-170, which encompass 'severe delay' to 'extremely high/gifted', higher numbers indicates higher intelligence. Score of 100 is expected mean standard score at each age interval. 95% children in each age group (based on normative sample) are expected to score within 2 SD of mean. | Analysis was performed on FAS population. No summary analysis was done and participant wise data were reported at available specified timepoints (most recent visit). Here, "Overall number of participants analyzed" signifies number of participants who were evaluated for this outcome measure. | Posted | Number | score on a scale | Participant-1: Week 156, Participant-2: Week 312, Participant-3: Week 416 |
|
|
|
| Secondary | Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Treatment-emergent Serious Adverse Events (TESAEs) | Adverse event (AE): any undesirable physical, psychological or behavioral effect experienced by participants during their participation in an investigational study, in conjunction with the use of the drug or biologic, whether or not product-related. Any untoward signs or symptoms experienced by the participant from the time of signing of the informed consent until completion of the study. Serious AE (SAE): any AE that resulted in any of the following outcomes: death, life-threatening experience, required hospitalization or prolonged inpatient hospitalization, persistent or significant disability/incapacity, congenital anomaly, and important medical events. TEAEs: AEs that developed, worsened, or became serious during the treatment-emergent period (defined as the period from the first study drug administration until last study assessment). | Analysis was performed on FAS. | Posted | Count of Participants | Participants | From Baseline up to 13.25 years |
|
|
|
| 3 |
| 12 |
| 9 |
| 12 |
| 11 |
| 12 |
| Bronchitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Catheter Site Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Device Related Sepsis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Gastroenteritis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Medical Device Site Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pneumonia Aspiration | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pneumonia Bacterial | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pseudomonas Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Syncytial Virus Bronchiolitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Sepsis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Vascular Device Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Acidosis | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Diabetes Mellitus | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Feeding Disorder | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoglycaemic Seizure | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Neurological Decompensation | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Seizure | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Cardio-Respiratory Arrest | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA 24.1 | Systematic Assessment |
|
| Apnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Bronchial Secretion Retention | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Chronic Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypercapnia | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pneumonitis | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pulmonary Hypertension | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Distress | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Velopharyngeal Incompetence | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dysphagia | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dermatitis Contact | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Glycogen Storage Disease Type Ii | Congenital, familial and genetic disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Oxygen Saturation Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Fungal Skin Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Influenza | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Oral Candidiasis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Otitis Media | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pharyngitis Streptococcal | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Pneumonia | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Rash Pustular | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Tract Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Rhinitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Upper Respiratory Tract Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Urinary Tract Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Viral Pharyngitis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Viral Upper Respiratory Tract Infection | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Vulvovaginal Candidiasis | Infections and infestations | MedDRA 24.1 | Systematic Assessment |
|
| Iron Deficiency Anaemia | Blood and lymphatic system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Allergy To Animal | Immune system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Multiple Allergies | Immune system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dehydration | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Diabetes Mellitus | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Feeding Disorder | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoglycaemia | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypokalaemia | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypophosphataemia | Metabolism and nutrition disorders | MedDRA 24.1 | Systematic Assessment |
|
| Areflexia | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Encephalopathy | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Focal Dyscognitive Seizures | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypotonia | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Seizure | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| White Matter Lesion | Nervous system disorders | MedDRA 24.1 | Systematic Assessment |
|
| Chalazion | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Eye Discharge | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Eye Swelling | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Eyelid Ptosis | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Papilloedema | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Visual Acuity Reduced | Eye disorders | MedDRA 24.1 | Systematic Assessment |
|
| Deafness | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Deafness Neurosensory | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| External Ear Disorder | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Middle Ear Effusion | Ear and labyrinth disorders | MedDRA 24.1 | Systematic Assessment |
|
| Right Ventricular Hypertrophy | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Sinus Tachycardia | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Tachycardia | Cardiac disorders | MedDRA 24.1 | Systematic Assessment |
|
| Flushing | Vascular disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypotension | Vascular disorders | MedDRA 24.1 | Systematic Assessment |
|
| Aspiration | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Asthma | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Atelectasis | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Bronchial Secretion Retention | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Bronchospasm | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dysphonia | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dyspnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Epistaxis | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypercapnia | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoventilation | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Increased Upper Airway Secretion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Nasal Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Oropharyngeal Pain | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pleural Effusion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Productive Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pulmonary Oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Distress | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Failure | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Respiratory Tract Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Rhinorrhoea | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Rhonchi | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Sinus Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Sneezing | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Stridor | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Upper Respiratory Tract Congestion | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Velopharyngeal Incompetence | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Constipation | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dental Caries | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Diarrhoea | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Gingival Swelling | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Mouth Ulceration | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Post-Tussive Vomiting | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Salivary Hypersecretion | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Swollen Tongue | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Teething | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Vomiting | Gastrointestinal disorders | MedDRA 24.1 | Systematic Assessment |
|
| Angioedema | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Decubitus Ulcer | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dermatitis Diaper | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Dry Skin | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Hair Growth Abnormal | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Papule | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Rash | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Rash Papular | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Skin Disorder | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Arthralgia | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Extremity Contracture | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Foot Deformity | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Joint Contracture | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Muscular Weakness | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Myopathy | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pain In Extremity | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Scoliosis | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Spinal Deformity | Musculoskeletal and connective tissue disorders | MedDRA 24.1 | Systematic Assessment |
|
| Nephrolithiasis | Renal and urinary disorders | MedDRA 24.1 | Systematic Assessment |
|
| Balanoposthitis | Reproductive system and breast disorders | MedDRA 24.1 | Systematic Assessment |
|
| Asthenia | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Catheter Site Rash | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Mass | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pain | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Pyrexia | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Swelling | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Swelling Face | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Unevaluable Event | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Vascular Device Occlusion | General disorders | MedDRA 24.1 | Systematic Assessment |
|
| Audiogram Abnormal | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Bacterial Test Positive | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Blood Potassium Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Blood Urine Present | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Body Temperature Increased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Clostridium Test Positive | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Electrocardiogram Qrs Complex Prolonged | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Electrocardiogram Qt Prolonged | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Electrocardiogram T Wave Inversion | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Fungal Test Positive | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Haematocrit Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Haemoglobin Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Oxygen Saturation Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Pseudomonas Test Positive | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Tympanometry Abnormal | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Urine Output Decreased | Investigations | MedDRA 24.1 | Systematic Assessment |
|
| Anaesthetic Complication | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Femur Fracture | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Joint Dislocation | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Procedural Pain | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Stoma Site Haemorrhage | Injury, poisoning and procedural complications | MedDRA 24.1 | Systematic Assessment |
|
| Device Malfunction | Product Issues | MedDRA 24.1 | Systematic Assessment |
|
The Sponsor supports publication of clinical trial results but may request that investigators temporarily delay or alter publications in order to protect proprietary information. The Sponsor may also require that the results of multicenter studies be published only in their entirety and not as individual site data.
| D002493 | Central Nervous System Diseases |
| D009422 | Nervous System Diseases |
| D008661 | Metabolism, Inborn Errors |
| D030342 | Genetic Diseases, Inborn |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D006008 | Glycogen Storage Disease |
| D002239 | Carbohydrate Metabolism, Inborn Errors |
| D016464 | Lysosomal Storage Diseases |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
|
| Participant-2 Baseline |
|
|
| Participant-2 Week 82 |
|
|
| Participant-3 Baseline |
|
|
| Participant-3 Week 208 |
|
|
| Participant-4 Baseline |
|
|
| Participant-4 Week 364 |
|
|
| Participant-5 Baseline |
|
|
| Participant-5 Week 12 |
|
|
| Participant-6 Baseline |
|
|
| Participant-6 Week 365 |
|
|
| Participant-7 Baseline |
|
|
| Participant-7 Week 64 |
|
|
| Participant-8 Baseline |
|
|
| Participant-8 Week 156 |
|
|
| Participant-9 Baseline |
|
|
| Participant-9 Week 364 |
|
|
| Participant-10 Baseline |
|
|
| Participant-10 Week 52 |
|
|
| Participant-11 Baseline |
|
|
| Participant-11 Week 156 |
|
|
| Participant-12 Baseline |
|
|
| Participant-12 Week 520 |
|
|
|
| Participant-2 Baseline |
|
|
| Participant-2 Week 82 |
|
|
| Participant-3 Baseline |
|
|
| Participant-3 Week 208 |
|
|
| Participant-4 Baseline |
|
|
| Participant-4 Week 208 |
|
|
| Participant-5 Baseline |
|
|
| Participant-5 Week 12 |
|
|
| Participant-6 Baseline |
|
|
| Participant-6 Week 365 |
|
|
| Participant-7 Baseline |
|
|
| Participant-7 Week 64 |
|
|
| Participant-8 Baseline |
|
|
| Participant-8 Week 156 |
|
|
| Participant-9 Baseline |
|
|
| Participant-9 Week 312 |
|
|
| Participant-10 Baseline |
|
|
| Participant-10 Week 52 |
|
|
| Participant-11 Baseline |
|
|
| Participant-11 Week 156 |
|
|
| Participant-12 Baseline |
|
|
| Participant-12 Week 468 |
|
|
|
| Participant-2 Baseline |
|
|
| Participant-2 Week 83 |
|
|
| Participant-3 Baseline |
|
|
| Participant-3 Week 104 |
|
|
| Participant-4 Baseline |
|
|
| Participant-4 Week 104 |
|
|
| Participant-5 Baseline |
|
|
| Participant-6 Baseline |
|
|
| Participant-6 Week 78 |
|
|
| Participant-7 Baseline |
|
|
| Participant-7 Week 26 |
|
|
| Participant-8 Baseline |
|
|
| Participant-8 Week 26 |
|
|
| Participant-9 Baseline |
|
|
| Participant-9 Week 156 |
|
|
| Participant-10 Baseline |
|
|
| Participant-10 Week 26 |
|
|
| Participant-11 Baseline |
|
|
| Participant-11 Week 26 |
|
|
| Participant-12 Baseline |
|
|
| Participant-12 Week 104 |
|
|
|
| Participant-2 Baseline |
|
|
| Participant-2 Week 52 |
|
|
| Participant-3 Baseline |
|
|
| Participant-3 Week 208 |
|
|
| Participant-4 Baseline |
|
|
| Participant-4 Week 208 |
|
|
| Participant-5 Baseline |
|
|
| Participant-6 Baseline |
|
|
| Participant-6 Week 359 |
|
|
| Participant-7 Baseline |
|
|
| Participant-7 Week 26 |
|
|
| Participant-8 Baseline |
|
|
| Participant-8 Week 156 |
|
|
| Participant-9 Baseline |
|
|
| Participant-9 Week 312 |
|
|
| Participant-10 Baseline |
|
|
| Participant-11 Baseline |
|
|
| Participant-11 Week 156 |
|
|
| Participant-12 Baseline |
|
|
| Participant-12 Week 416 |
|
|
|
| Participant-1 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-1 Week 52: Caregiver Assistance- Self-Care |
|
|
| Participant-1 Baseline: Functional Skills- Mobility |
|
|
| Participant-1 Week 52: Functional Skills- Mobility |
|
|
| Participant-1 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-1 Week 52: Caregiver Assistance- Mobility |
|
|
| Participant-1 Baseline: Functional Skills- Social |
|
|
| Participant-1 Week 52: Functional Skills- Social |
|
|
| Participant-1 Baseline: Caregiver Assistance- Social |
|
|
| Participant-1 Week 52: Caregiver Assistance- Social |
|
|
| Participant-2 Baseline: Functional Skills- Self-Care |
|
|
| Participant-2 Week 52: Functional Skills- Self-Care |
|
|
| Participant-2 Week 52: Caregiver Assistance- Self-Care |
|
|
| Participant-2 Baseline: Functional Skills- Mobility |
|
|
| Participant-2 Week 52: Functional Skills- Mobility |
|
|
| Participant-2 Week 52: Caregiver Assistance- Mobility |
|
|
| Participant-2 Week 52: Functional Skills- Social |
|
|
| Participant-3 Baseline: Functional Skills-Self-Care |
|
|
| Participant-3 Week 208: Functional Skills- Self-Care |
|
|
| Participant-3 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-3 Week 208: Caregiver Assistance- Self-Care |
|
|
| Participant-3 Baseline: Functional Skills- Mobility |
|
|
| Participant-3 Week 208: Functional Skills- Mobility |
|
|
| Participant-3 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-3 Week 208: Caregiver Assistance- Mobility |
|
|
| Participant-3 Baseline: Functional Skills- Social |
|
|
| Participant-3 Week 208: Functional Skills- Social |
|
|
| Participant-3 Baseline: Caregiver Assistance- Social |
|
|
| Participant-3 Week 208: Caregiver Assistance- Social |
|
|
| Participant-4 Baseline: Functional Skills- Self-Care |
|
|
| Participant-4 Week 208: Functional Skills- Self-Care |
|
|
| Participant-4 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-4 Week 208: Caregiver Assistance- Self-Care |
|
|
| Participant-4 Baseline: Functional Skills- Mobility |
|
|
| Participant-4 Week 208: Functional Skills- Mobility |
|
|
| Participant-4 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-4 Week 208: Caregiver Assistance- Mobility |
|
|
| Participant-4 Baseline: Functional Skills- Social |
|
|
| Participant-4 Week 208: Functional Skills-Social |
|
|
| Participant-4 Baseline: Caregiver Assistance- Social |
|
|
| Participant-4 Week 208: Caregiver Assistance- Social |
|
|
| Participant-5 Baseline: Functional Skills- Self-Care |
|
|
| Participant-5 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-5 Baseline: Functional Skills- Mobility |
|
|
| Participant-5 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-5 Baseline: Functional Skills- Social |
|
|
| Participant-5 Baseline: Caregiver Assistance- Social |
|
|
| Participant-6 Baseline: Functional Skills-Self-Care |
|
|
| Participant-6 Week 359: Functional Skills-Self-Care |
|
|
| Participant-6 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-6 Week 359: Caregiver Assistance- Self-Care |
|
|
| Participant-6 Baseline: Functional Skills- Mobility |
|
|
| Participant-6 Week 359: Functional Skills- Mobility |
|
|
| Participant-6 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-6 Week 359: Caregiver Assistance- Mobility |
|
|
| Participant-6 Baseline: Functional Skills- Social |
|
|
| Participant-6 Week 359: Functional Skills-Social |
|
|
| Participant-6 Baseline: Caregiver Assistance- Social |
|
|
| Participant-6 Week 359: Caregiver Assistance- Social |
|
|
| Participant-7 Baseline: Functional Skills- Self-Care |
|
|
| Participant-7 Week 52: Functional Skills-Self-Care |
|
|
| Participant-7 Week 52: Caregiver Assistance- Self-Care |
|
|
| Participant-7 Baseline: Functional Skills- Mobility |
|
|
| Participant-7 Week 52: Functional Skills- Mobility |
|
|
| Participant-7 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-7 Week 52: Caregiver Assistance- Mobility |
|
|
| Participant-7 Baseline: Functional Skills- Social |
|
|
| Participant-7 Week 52: Functional Skills-Social |
|
|
| Participant-7 Baseline: Caregiver Assistance- Social |
|
|
| Participant-7 Week 52: Caregiver Assistance- Social |
|
|
| Participant-8 Baseline: Functional Skills- Self-Care |
|
|
| Participant-8 Week 156: Functional Skills- Self-Care |
|
|
| Participant-8 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-8 Week 156: Caregiver Assistance- Self-Care |
|
|
| Participant-8 Baseline: Functional Skills- Mobility |
|
|
| Participant-8 Week 156: Functional Skills- Mobility |
|
|
| Participant-8 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-8 Week 156: Caregiver Assistance- Mobility |
|
|
| Participant-8 Baseline: Functional Skills- Social |
|
|
| Participant-8 Week 156: Functional Skills-Social |
|
|
| Participant-8 Baseline: Caregiver Assistance- Social |
|
|
| Participant-8 Week 156: Caregiver Assistance- Social |
|
|
| Participant-9 Baseline: Functional Skills-Self-Care |
|
|
| Participant-9 Week 312: Functional Skills-Self-Care |
|
|
| Participant-9 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-9 Week 312: Caregiver Assistance- Self-Care |
|
|
| Participant-9 Baseline: Functional Skills- Mobility |
|
|
| Participant-9 Week 312: Functional Skills- Mobility |
|
|
| Participant-9 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-9 Week 312 :Caregiver Assistance- Mobility |
|
|
| Participant-9 Baseline: Functional Skills- Social |
|
|
| Participant-9 Week 312: Functional Skills-Social |
|
|
| Participant-9 Baseline: Caregiver Assistance- Social |
|
|
| Participant-9 Week 312: Caregiver Assistance- Social |
|
|
| Participant-10 Baseline: Functional Skills-Self-Care |
|
|
| Participant-10 Week 26: Functional Skills- Self-Care |
|
|
| Participant-10 Baseline: Caregiver Assistance Self-Care |
|
|
| Participant-10 Week 26: Caregiver Assistance- Self-Care |
|
|
| Participant-10 Baseline: Functional Skills- Mobility |
|
|
| Participant-10 Week 26: Functional Skills- Mobility |
|
|
| Participant-10 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-10 Week 26: Caregiver Assistance- Mobility |
|
|
| Participant-10 Baseline: Functional Skills- Social |
|
|
| Participant-10 Week 26: Functional Skills- Social |
|
|
| Participant-10 Baseline: Caregiver Assistance- Social |
|
|
| Participant-10 Week 26: Caregiver Assistance- Social |
|
|
| Participant-11 Baseline: Functional Skills- Self-Care |
|
|
| Participant-11 Week 156: Functional Skills- Self-Care |
|
|
| Participant-11 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-11 Week 156: Caregiver Assistance- Self-Care |
|
|
| Participant-11 Baseline: Functional Skills- Mobility |
|
|
| Participant-11 Week 156: Functional Skills- Mobility |
|
|
| Participant-11 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-11 Week 156: Caregiver Assistance- Mobility |
|
|
| Participant-11 Baseline: Functional Skills-Social |
|
|
| Participant-11 Week 156: Functional Skills- Social |
|
|
| Participant-11 Baseline: Caregiver Assistance- Social |
|
|
| Participant-11 Week 156: Caregiver Assistance- Social |
|
|
| Participant-12 Baseline: Functional Skills- Self-Care |
|
|
| Participant-12 Week 416: Functional Skills-Self-Care |
|
|
| Participant-12 Baseline: Caregiver Assistance- Self-Care |
|
|
| Participant-12 Week 416: Caregiver Assistance- Self-Care |
|
|
| Participant-12 Baseline: Functional Skills- Mobility |
|
|
| Participant-12 Week 416: Functional Skills- Mobility |
|
|
| Participant-12 Baseline: Caregiver Assistance- Mobility |
|
|
| Participant-12 Week 416: Caregiver Assistance- Mobility |
|
|
| Participant-12 Baseline: Functional Skills- Social |
|
|
| Participant-12 Week 416: Functional Skills- Social |
|
|
| Participant-12 Baseline: Caregiver Assistance- Social |
|
|
| Participant-12 Week 416: Caregiver Assistance- Social |
|
|
|
| Participant-2 Baseline: Cognitive |
|
|
| Participant-2 Week 83: Cognitive |
|
|
| Participant-3 Baseline: Cognitive |
|
|
| Participant-3 Week 104: Cognitive |
|
|
| Participant-4 Baseline: Cognitive |
|
|
| Participant-4 Week 104: Cognitive |
|
|
| Participant-5 Baseline: Cognitive |
|
|
| Participant-6 Baseline: Cognitive |
|
|
| Participant-6 Week 78: Cognitive |
|
|
| Participant-7 Baseline: Cognitive |
|
|
| Participant-7 Week 26: Cognitive |
|
|
| Participant-8 Baseline: Cognitive |
|
|
| Participant-8 Week 26: Cognitive |
|
|
| Participant-9 Baseline: Cognitive |
|
|
| Participant-9 Week 156: Cognitive |
|
|
| Participant-10 Baseline: Cognitive |
|
|
| Participant-10 Week 26: Cognitive |
|
|
| Participant-11 Baseline: Cognitive |
|
|
| Participant-11 Week 26: Cognitive |
|
|
| Participant-12 Baseline: Cognitive |
|
|
| Participant-12 Week 104: Cognitive |
|
|
| Participant-1 Baseline: Language |
|
|
| Participant-1 Week 52: Language |
|
|
| Participant-2 Baseline: Language |
|
|
| Participant-2 Week 83: Language |
|
|
| Participant-3 Baseline: Language |
|
|
| Participant-3 Week 104: Language |
|
|
| Participant-4 Baseline: Language |
|
|
| Participant-4 Week 104: Language |
|
|
| Participant-5 Baseline: Language |
|
|
| Participant-6 Baseline: Language |
|
|
| Participant-6 Week 78: Language |
|
|
| Participant-7 Baseline: Language |
|
|
| Participant-7 Week 26: Language |
|
|
| Participant-8 Baseline: Language |
|
|
| Participant-8 Week 26: Language |
|
|
| Participant-9 Baseline: Language |
|
|
| Participant-9 Week 156: Language |
|
|
| Participant-10 Baseline: Language |
|
|
| Participant-10 Week 26: Language |
|
|
| Participant-11 Baseline: Language |
|
|
| Participant-11 Week 26: Language |
|
|
| Participant-12 Baseline: Language |
|
|
| Participant-12 Week 104: Language |
|
|
|
| Participant-3 Week 260 |
|
|
| Participant-4 Week 156 |
|
|
| Participant-5 Week 208 |
|
|
|
| Participant-3 Week 416 |
|
|